HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Quote:
Login Free Membership
Search:

Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros


Zacks Commentary: Timely Buy Of The Week

  PRINTABLE VERSION  
Perrigo Company
Oct 30, 2008
Perrigo Company (PRGO) is in one of the sectors that investors have been flocking to during the market downturn: health care.

The company, a Zacks #1 Rank (strong buy), which manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products and consumer products, is expanding as consumers switch from more expensive, brand-name products to cheaper items in a slowing economy.

Perrigo is one of the largest suppliers of branded products to retailers. It supplies products in more than 15 categories and 500 formulas and offers analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as well as vitamins, dietary supplements and nutritional drinks.

Perrigo Gets Tentative Approval for Ibuprofen PM

Perrigo continues to invest in new generic products. On Oct 29, PRGO announced it received tentative approval from the FDA for its over-the-counter Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg., which is a pain reliever/nighttime sleep aid.

The company estimates that brand sales for the product for the prior 12 months ending Sept 30, 2008 were $70 million.

Perrigo is a Value Stock

Analysts continue to be bullish about Perrigo's future. 2008 year-over-year growth is expected to be 24.05%.

Full year 2009 estimates are up 4 cents to $1.96 in the last 60 days. Estimates for the first-quarter 2009 are up 2 cents to 42 cents in the last 30 days.

Perrigo has a forward P/E of 14.8. Its price-to-book is 3.0. PRGO has a stellar 1-year return on equity (ROE) of 17.5%.

The company has surprised on earnings 3 out of 4 quarters by an average of 11.65%. It reports first-quarter 2009 earnings on Nov 6.

Bookmark and Share        Email        Feedback          Print       

ZACKS COMMENTARY: TIMELY BUY OF THE WEEK ARCHIVE


 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research